Abstract
Severe acute respiratory diseases caused by coronavirus disease 2019 (COVID-19) have caused infections around the world, and this disease has been declared a global pandemic by the World Health Organization. COVID-19 has severely impacted the world economy, and as it has multiple unnoticeable transmission routes, it can derail the health care system for a long time. Most states in India are affected by the COVID pandemic. As India is known for its seasonal infections such as dengue, leptospirosis, influenza, malaria, and enteric fever, it is expected that these infections may co-exist. Coinfection of these two viral infections causes challenges in diagnosis and treatment, especially in places with limited resources. Antibody-mediated enhancement of the immune response is a cause for concern in co-infection of COVID-19 and dengue. The present article discusses the clinical features, serological cross reactions, and antibody-dependent enhancement of COVID-19 coinfection with dengue infection.
Highlights
Coronavirus SARS-CoV-2 (COVID-19) is a respiratory disease that originated in December 2019 in the Wuhan district, Hubei Province, China
Severe acute respiratory diseases caused by coronavirus disease 2019 (COVID-19) have caused infections around the world, and this disease has been declared a global pandemic by the World Health Organization
Though COVID-19 and dengue viral infection are similar in their clinical manifestations and laboratory parameters, including thrombocytopenia and leukopenia, they differ in their management and treatment modalities
Summary
Coronavirus SARS-CoV-2 (COVID-19) is a respiratory disease that originated in December 2019 in the Wuhan district, Hubei Province, China. Coinfection of these two viral infections causes challenges in diagnosis and treatment, especially in places with limited resources. Antibody-mediated enhancement of the immune response is a cause for concern in co-infection of COVID-19 and dengue.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
